🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to health experts.

An International Challenge

Cases of gonorrhoea are on the rise globally, with figures suggesting more than 82 million new cases each year. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the face of growing infection rates, escalating drug resistance and the very limited available drugs currently available.”

Medical experts are deeply concerned about the rise in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval signifies a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Data and Global Access

Based on data published in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves an injection and a pill. The research included hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed positive views. Having a one-pill regimen such as this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea globally.